Sanjivani Paranteral Ltd (531569)
Quarter ended 30th June, 2026
Press Release - Q1FY27
- Consolidated revenue 238.39 Mn +33.8% y-y; EBITDA 43.21 Mn (margin 18.0%); PAT 24.91 Mn +43.9% y-y
- FY27 revenue guidance: base business ₹800–850 Mn, Pune IV fluids ₹600–650 Mn
- EBITDA margin guided at 16–17% supported by USD strength despite logistics cost pressures
- Injectables growth expected 10–12%, tablets 7–8%, nutraceuticals 8–9% in FY27
- Pune IV fluid plant to reach 70% utilisation in FY27 with breakeven expected
- Export share ~78.5% of revenue; alternate shipping routes restored after Q4 disruption
- Management expects recovery from Q1 FY27 after March 2026 Middle East logistics disruption
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 531569 — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add 531569 to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Sanjivani Paranteral Ltd
Important.
The summary above is generated automatically from Sanjivani Paranteral Ltd's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.